comparemela.com

Page 8 - Dana Cormack News Today : Breaking News, Live Updates & Top Stories | Vimarsana

REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy

/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-202,.

Dana cormackChris brinzeyDebra millerTechnology platform licenseesExchange commissionSecurities exchangeClinical programCorporate communicationsDrug administrationManufacturing innovation centerTechnology platformInnovation centerFast trackDrug designationRare pediatric diseaseChief executive officer

REGENXBIO to Participate in Upcoming Investor Conferences

/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Barclays Global Healthcare.

United statesDana cormackChris brinzeyTechnology platformCorporate communicationsTechnology platform licenseesPanel timeChat dateChat timeSpotlight seriesNovel technologiesGenetic medicines panelTargeting diverseBarclays global healthcare conferencePlatform licenseesRegenxbio inc

REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights

Continued progress on 5x 25 strategy to advance five AAV Therapeutics from REGENXBIO s internal pipeline and licensed programs into pivotal-stage or.

United statesUnited kingdomDana cormackChris brinzeyUltragenyx pharmaceutical incTechnology platformTechnology platform licenseesRocket pharmaceuticals incUnited kingdom health authorityTechnology licensee programDevelopment expensesExchange commissionCorporate communicationsSecurities exchangeManufacturing innovation centerChief executive officer

Additional Positive Interim Data from Phase I/II Trial of REGENXBIO S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™

RGX-111 is an investigational AAV Therapeutic for the treatment of severe MPS I that is part of REGENXBIO s clinical-stage pipeline of neurodegenerative.

United statesRay wangDana cormackChris brinzeyUniversity of californiaMultidisciplinary lysosomal programTechnology platformTechnology platform licenseesDivision of metabolic disordersDrug administrationCampbell foundationScales of infant developmentExchange commissionCorporate communicationsSecurities exchangeDepartment of pediatrics

Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO s RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM

RGX-121, a potential one-time gene therapy for the treatment of MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels.

United statesDana cormackChris brinzeySteve pakolaToddler developmentTechnology platformTechnology platform licenseesDrug administrationPerelman school of medicineExchange commissionCorporate communicationsUniversity of pennsylvaniaSecurities exchangeBiologics license applicationMucopolysaccharidosis typeChief medical officer

vimarsana © 2020. All Rights Reserved.